BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics

BACKGROUND: Coagulation factor XI (FXI) contributes to the development of thrombosis but appears to play only a minor role in hemostasis and is therefore an attractive anticoagulant drug target. OBJECTIVES: To evaluate the safety, pharmacodynamic, and pharmacokinetic properties of BAY 1213790, a ful...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Dirk, Thelen, Kirstin, Kraff, Stefanie, Schwers, Stephan, Schiffer, Sonja, Unger, Sigrun, Yassen, Ashraf, Boxnick, Stefanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles: Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462747/
https://www.ncbi.nlm.nih.gov/pubmed/31011708
http://dx.doi.org/10.1002/rth2.12186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462747/
https://www.ncbi.nlm.nih.gov/pubmed/31011708
http://dx.doi.org/10.1002/rth2.12186

Ejemplares similares